Medidata Launches New AI Solution to Modernize the Data Experience in Clinical Trials

What You Should Know:

–       Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data.

–       This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients faster. 

Revolutionizing Clinical Trials with Medidata’s Unified Platform and AI-Powered Insights

Built on the industry’s only unified platform, Clinical Data Studio integrates data from both Medidata and non-Medidata sources, accelerating decision-making across the full clinical trial process. It delivers holistic data and risk strategies that connect patients, sites, and sponsors. Through AI, study teams can more effectively identify potential data issues and safety signals, resulting in a more accurate understanding of the patient.

 This approach reduces the challenges posed by siloed data systems and enables data review and reconciliation up to 80 percent faster. Clinical Data Studio offers a comprehensive workspace for data integration, transformation, and management. It includes AI-assisted data reconciliation and anomaly detection, self-serve data listings, robust risk-based quality management, and tools to implement a holistic data and risk strategy supported by workflows and visualizations.

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of groundbreaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world.

“Clinical Data Studio unlocks the broad ecosystem of clinical data. Powered by embedded AI, we are democratizing access to data and revealing the signals, risks, and insights that matter most. Together this accelerates trial execution and creates rich data for new discoveries,” said Tom Doyle, chief technology officer, Medidata.